ProJenX
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
New York City, New York, United StatesWebsite
www.projenx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ProJenX
ProJenX is a clinical-stage biotechnology company developing novel, targeted brain penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. At the heart of ProJenXs approach is an innovative, patient-specific, cell-based drug discovery platform. Through a long-term research collaboration between Project ALS and researchers at Columbia University, the company's team drove breakthroughs in stem cell biology and created the first ALS patient-derived disease models. These models drove insights into what goes wrong with motor neurons, the brain cells affected by ALS and how to rescue them.Explore more
ProJenX Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ProJenX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when ProJenX launches new products
ProJenX, which may be a good buyer, showed buying intent in Masked Content Topic
Check if ProJenX has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once ProJenX has new funding data
Click to see if ProJenX had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ProJenX
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on ProJenX recently announced quarterly report
Check out if ProJenX is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined ProJenX as Masked Content
Find 2 more new buyers
Compare Similar Companies to ProJenX
Compare insights from companies similar to ProJenX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ProJenX is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ProJenX is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ProJenX.
ProJenX financials insights
Gather financial insights about ProJenX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$15M
ProJenX Tech Stack
A closer look at the technologies used by ProJenX
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Compliance, Legal Affairs
Funding
Funding
ProJenX News & Media
ProJenX Announces Formation of Clinical Advisory Board
NEW YORK, Aug. 27, 2024 /PRNewswire/ -- ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced...ProJenX Announces Receipt of $1M Hoffman ALS Clinical Trial Award from the ALS Association
Funding will support the first study of prosetin in people living with ALS NEW YORK, June 20, 2024 /PRNewswire/ -- ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic...ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA
Prosetin is a novel, brain-penetrant, MAP4 kinase inhibitor that has shown potent motor neuron protection in preclinical models of ALS On track to initiate enrollment in participants with ALS in Q2 2024 at clinical sites in Canada and the Netherlands, with US sites to be added later this...ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS
NEW YORK, Feb. 14, 2024 /PRNewswire/ -- ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other debilitating brain diseases, today announced that...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding ProJenX
Sign Up For FreeTo access detailed company insights
ProJenX is a clinical-stage biotechnology company developing novel, targeted brain penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. At the heart of ProJenXs approach is an innovative, patient-specific, cell-based drug discovery platform. Through a long-term research collaboration between Project ALS and resea... Read More
